Kevin X. Le
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kevin X. Le has a total of 279 co-authors. Here are the top co-authors by number of shared publications:
A. Holmes
1 shared publication- Adriana Migliorini
McEwen Stem Cell Institute, University Health Network, Toronto, ON M5G 1L7, Canada
1 shared publication - Ajaib Singh Paintlia
Department of Pediatrics, Medical University of South Carolina, Charleston, South Carolina 29425, USA
1 shared publication - Akihiko Okuda
Division of Biomedical Sciences, Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Japan
1 shared publication Alec Falkenham
1 shared publication- Alexander Dietrich
German Aerospace Center (DLR), Institute of Robotics and Mechatronics, Wessling, Germany
1 shared publication
Latest Publications
- Top Cited Papers
- 31 May 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9  (392)
Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice
The complement cascade not only is an innate immune response that enables removal of pathogens but also plays an important role in microglia-mediated synaptic refinement during brain development. Complement C3 is elevated in Alzheimerâs disease (AD), colocalizing with neuritic plaques, and appears to contribute to clearance of AÎČ by microglia in the brain. Previously, we reported that C3-deficient C57BL/6 mice were protected against age-related and region-specific loss of hippocampal synapses and cognitive decline during normal aging. Furthermore, blocking complement and downstream iC3b/CR3 signaling rescued synapses from AÎČ-induced loss in young AD mice before amyloid plaques had accumulated. We assessed the effects of C3 deficiency in aged, plaque-rich APPswe/PS1dE9 transgenic mice (APP/PS1;C3 KO). We examined the effects of C3 deficiency on cognition, AÎČ plaque deposition, and plaque-related neuropathology at later AD stages in these mice. We found that 16-month-old APP/PS1;C3 KO mice performed better on a learning and memory task than did APP/PS1 mice, despite having more cerebral AÎČ plaques. Aged APP/PS1;C3 KO mice also had fewer microglia and astrocytes localized within the center of hippocampal AÎČ plaques compared to APP/PS1 mice. Several proinflammatory cytokines in the brain were reduced in APP/PS1;C3 KO mice, consistent with an altered microglial phenotype. C3 deficiency also protected APP/PS1 mice against age-dependent loss of synapses and neurons. Our study suggests that complement C3 or downstream complement activation fragments may play an important role in AÎČ plaque pathology, glial responses to plaques, and neuronal dysfunction in the brains of APP/PS1 mice.
- 31 May 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9  (392)
Top Cited PapersComplement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice
The complement cascade not only is an innate immune response that enables removal of pathogens but also plays an important role in microglia-mediated synaptic refinement during brain development. Complement C3 is elevated in Alzheimerâs disease (AD), colocalizing with neuritic plaques, and appears to contribute to clearance of AÎČ by microglia in the brain. Previously, we reported that C3-deficient C57BL/6 mice were protected against age-related and region-specific loss of hippocampal synapses and cognitive decline during normal aging. Furthermore, blocking complement and downstream iC3b/CR3 signaling rescued synapses from AÎČ-induced loss in young AD mice before amyloid plaques had accumulated. We assessed the effects of C3 deficiency in aged, plaque-rich APPswe/PS1dE9 transgenic mice (APP/PS1;C3 KO). We examined the effects of C3 deficiency on cognition, AÎČ plaque deposition, and plaque-related neuropathology at later AD stages in these mice. We found that 16-month-old APP/PS1;C3 KO mice performed better on a learning and memory task than did APP/PS1 mice, despite having more cerebral AÎČ plaques. Aged APP/PS1;C3 KO mice also had fewer microglia and astrocytes localized within the center of hippocampal AÎČ plaques compared to APP/PS1 mice. Several proinflammatory cytokines in the brain were reduced in APP/PS1;C3 KO mice, consistent with an altered microglial phenotype. C3 deficiency also protected APP/PS1 mice against age-dependent loss of synapses and neurons. Our study suggests that complement C3 or downstream complement activation fragments may play an important role in AÎČ plaque pathology, glial responses to plaques, and neuronal dysfunction in the brains of APP/PS1 mice.
- 1 August 2013
- Published by Elsevier in The American Journal of Pathology
- Vol. 183  (2) , A3-A6
Table of Contents
- 1 August 2013
- Published by Elsevier in The American Journal of Pathology
- Vol. 183  (2) , A3-A6
Table of Contents